|Table of Contents|

Abortion increases the incidence of long-term adverse cardiovascular events in patients with triple-negative breast cancer after chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 17
Page:
3254-3259
Research Field:
Publishing date:

Info

Title:
Abortion increases the incidence of long-term adverse cardiovascular events in patients with triple-negative breast cancer after chemotherapy
Author(s):
CHENG Xingxing; GUO Jun; WU Jiang; CHENG Wei; XU Li; ZHONG Hui
Daye People's Hospital，Hubei Daye 435100，China.
Keywords:
abortion; triple-negative breast cancer; major adverse cardiovascular events; predictors
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.17.014
Abstract:
Objective:To explore the relationship between abortion and cancer and cardiovascular diseases,and to provide a new research direction for the evaluation of long-term adverse cardiovascular events in breast cancer patients after chemotherapy.Methods:Clinical data of patients with triple negative breast cancer diagnosed in Daye People's Hospital from 2016 to 2019 were collected.All patients were divided into abortion group and non-abortion group，analysis of two subgroups of abortion group：artificial abortion group and natural abortion group.All patients were followed up and the incidence of major adverse cardiovascular events,all-cause mortality and cardiovascular mortality were compared between the two groups within 3 years,multivariate Cox regression was used to analyze risk factors for major adverse cardiovascular events,and Kaplan-Meier survival curves were used to analyze the effect of abortion on triple-negative breast cancer mortality and major adverse cardiovascular events.Results:The results of this study showed that when the baseline of the abortion group was compared with that of the non-abortion group,there was no significant difference in age,smoking history,drinking history,hypertension,use of dextranimide,radiotherapy between the two groups(P＞0.05).There were significant differences between groups with or without operation history and chemotherapy course at baseline(P＜0.05).Major adverse cardiovascular events occurred in 5.5% of all patients with breast cancer within 3 years in both groups,and all-cause mortality was approximately 15.7%,compared with 1.5% for cardiovascular causes.Comparing the abortion group with the non-abortion group,the abortion group had a higher rate of major adverse cardiovascular events at 3 years(15.6% vs 3.4%,P＜0.05) and a higher rate of all-cause mortality(29.4% vs 11.0%,P＜0.05).There was no significant difference in cardiovascular mortality between the abortion group and the non-abortion group(7.8% vs 0.7%,P＞0.05).Cox regression analysis showed that abortion,age,operation,chemotherapy course and radiotherapy were independent risk factors of major adverse cardiovascular events in 3 years.There was no significant correlation between smoking history,hypertension history,use of dextromethamine and 3-year incidence of major adverse cardiovascular events(P＞0.05).In subgroup analysis,there was no statistically significant difference in the incidence of major adverse cardiovascular events,all-cause mortality rate,and cardiovascular mortality rate between the induced abortion group and the natural abortion group at 3 years.By Kaplan-Meier survival analysis,the 3-year rate of major adverse cardiovascular events was significantly higher in the abortion group than in the non-abortion group(P＜0.05).Conclusion:Abortion can increase the long-term adverse cardiovascular events in triple-negative breast cancer patients after chemotherapy.

References:

[1] 姜萌,卜军.肿瘤心脏病学研究年度进展2022［J］.中华医学杂志,2023,103(6):457-460. JIANG M,PU J.Annual progress in cancer cardiology research 2022［J］.National Medical Journal of China,2023,103(6):457-460.
[2] 王阿曼，方凤奇，夏云龙，等.肿瘤靶向治疗的心血管毒性研究进展［J］.现代肿瘤医学，2018，26(2)：291-296. WANG AM,FANG FQ,XIA YL,et al.Research progress on cardiovascular toxicity in tumor targeted therapy［J］.Modern Oncology，2018，26(2)：291-296.
[3] 周彦君,李秋月,胡宇乐，等.乳腺癌蒽环类化疗相关心脏毒性早期识别及预防的研究进展［J］.中华护理杂志,2023,58(7):816-821. ZHOU YJ,LI QY,HU YL，et al.Research progress on early recognition and prevention of cardiotoxicity related to anthracycline chemotherapy in breast cancer［J］.Chinese Journal of Nursing,2023,58(7):816-821.
[4] LEVICK SP，SOTO-PANTOJA DR，BI J，et al.Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts［J］.Heart Lung Circ，2018，28（10）：1598-1605.
[5] 陈安莉,沈浩元,王舒.三阴性乳腺癌新辅助治疗的临床研究进展［J］.现代肿瘤医学,2023,31(3):566-571. CHEN AL,SHENG HY,WANG S.Clinical research progress of neoadjuvant therapy for triple negative breast cancer［J］.Modern Oncology,2023,31(3):566-571.
[6] HEIDA,KARST Y,KOSTER,et al.Relationship between recurrent miscarriage and early preterm delivery and recurrent events in patients with manifest vascular disease：The SMART study［J］.European Journal of Preventive Cardiology,2016,23(5):486-492.
[7] 杨开华.三阴性乳腺癌预后的影响因素［J］.中国当代医药,2023,30(2):109-113. YANG KH.Factors influencing the prognosis of triple negative breast cancer［J］.Chinese Contemporary Medicine,2023,30(2):109-113.
[8] NICOLE M,LEOCE,ZHEZHEN,et al.Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer［J］.Breast Cancer Research,2021,23(1):91.
[9] MARISE M,WAGNER,MARY M,et al.Increased cardiovascular disease risk in women with a history of recurrent miscarriage［J］.Acta Obstetricia et Gynecologica Scandinavica,2018,97(10):1192-1199.
[10] CHRISTOS,PAPAGEORGIOU,ANGELIKI,et al.Cardiovascular toxicity of breast cancer treatment：an update［J］.Cancer Chemotherapy and Pharmacology,2021,88(1):15-24.
[11] SUSMITA,PARASHAR,NAUSHEEN,et al.Cancer treatment-related cardiovascular toxicity in gynecologic malignancies：JACC：CardioOncology State-of-the-Art Review［J］.JACC CardioOncology,2023,5(2):159-173.
[12] MENA S,TIRAPU S,VILLANUEVA V,et al.Cancer,onco-haematological treatment and cardiovascular toxicity［J］.Hipertension Riesgo Vascular,2021,38(2):72-82.
[13] JOACHIM,ALEXANDRE,JENNIFER,et al.Cardiovascular toxicity related to cancer treatment：A pragmatic approach to the American and European Cardio-Oncology Guidelines［J］.Journal of the American Heart Association,2020,9(18):e018403.
[14] MARTHA,GULATI,SHARON L,et al.The connection between the breast and heart in a woman：Breast cancer and cardiovascular disease［J］.Clinical Cardiology,2018,41(2):253-257.
[15] 李佳名,刘俊兰,陈侠,等.乳腺癌治疗相关心血管不良事件的诊治进展［J］.现代肿瘤医学，2020,28(08):1394-1397. LI JM,LIU JL,CHEN X,et al.Advances in diagnosis and treatment of cardiovascular adverse events associated with breast cancer treatment［J］.Modern Oncology,2020,28(08):1394-1397.
[16] HARRY,KYRIACOU,ABDULRAHMAN,et al.The risk of cardiovascular diseases after miscarriage,stillbirth,and induced abortion：a systematic review and meta-analysis［J］.European Heart Journal Open,2022,2(5):oeac065.

Memo

Memo:
-
Last Update: 2024-07-31